The AutoQUANT , Quantitative Perfusion SPECT (QPS), and Quantitative Gated SPECT (QGS) applications are intended to enable a fully automated review and quantification of Cardiac SPECT data.

Device Description

AutoQUANT is a software application designed to enable a fully automated, comprehensive review and quantification of Cardiac SPECT data within a suite of applications. AutoQUANT can operate as an independent single application or can be integrated into an application containing Quantitative Perfusion SPECT (QPS) and/or Quantitative Gated SPECT (QGS). AutoQUANT provides a tool to review and quantify all types of Cardiac SPECT data sets (perfusion and/or gated) to determine the location, orientation, and anatomical extent of the left ventricle of the heart, to construct 3D contour maps of the heart, and to calculate the heart volume (for the left ventricular wall), the lung/heart ratio, and transient ischemic dilation (TID). Physicians use this information to assess the anatomical and physiological functionality of the heart and analyze the presence of myocardial defects through comprehensive imaging modalities.

Quantitative Perfusion SPECT (QPS) is a software application designed for the review and quantification of myocardial perfusion SPECT short axis data. QPS can operate as an independent single application or as an embedded function packaged with AutoQUANT. Using the QPS application, myocardial rest and stress short axis projections (standard and gated Cardiac SPECT) can be reviewed and compared, the extent and volume of cardiac defects can be calculated, and 3D and 2D perfusion maps can be generated. The QPS application can also be used to create a user-definable Normal database (with definable normal limits) for review, quantification, and comparison.

Quantitative Gated SPECT (QGS) is a software application designed to view and analyze processed SPECT short axis or gated short axis data sets. QGS can operate as an independent single application or as an embedded function packaged with AutoQUANT. Using the QGS application, myocardial gated short axis projections can be reviewed and compared, the extent and severity of cardiac defects can be calculated, and 3D and 2D wall thickening, wall motion and regional ejection fraction maps can be generated. The application can be used to display the left ventricular endocardial and epicardial surfaces; polar maps indicating perfusion, wall thickening, wall motion, and regional ejection fraction: standard cardiac SPECT short axis and horizontal slices; and 3D cardiac surfaces and volumes from gated SPECT data. When using gated SPECT data, the left ventricular volume and left ventricular ejection fraction (LVEF) can be automatically calculated or regions may be manually specified for calculation. When using non-gated short axis SPECT data, the left ventricular volume can be calculated automatically or manually.

AI/ML Overview

I am sorry, but the provided text from the 510(k) notification does not contain information about specific acceptance criteria or a detailed study that proves the device meets those criteria.

The document states:

"Testing was conducted to demonstrate that each software application functioned as per its specifications. All tests passed with the actual results matching the expected results."

This statement confirms that some testing was done to ensure the software met its specifications, but it does not provide:

Specific acceptance criteria: It doesn't define what "per its specifications" entails in terms of quantifiable metrics or performance thresholds (e.g., accuracy, precision, error rates for cardiac measurements).
A detailed study description: There is no information on the methodology of the testing, such as sample size, data provenance, ground truth establishment, or any comparative effectiveness studies.

Therefore, I cannot extract the requested information in the format you provided. The document primarily focuses on the device description, indications for use, and a general statement about software functional testing, rather than a clinical or performance validation study with specific acceptance criteria.

Summary

{0}------------------------------------------------

AutoQUANT, Quantitative Perfusion SPECT (QPS), & Quantitative Gated SPECT (QGS)
ADAC Laboratories
510(k) Premarket Notification

Appendix VIII, 510(k) Summary of Safety and Effectiveness Data
Page 1 of 3

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS DATA

I. General Information
A. Submitted By:

K980715

ADAC Laboratories 540 Alder Drive Milpitas, CA 95035 Tel: (408) 321-9100 Fax: (408) 321-9686

Contact Person:

Dennis Henkelman at address above

AutoOUANT Device Trade Name: B. Quantitative Perfusion SPECT (QPS) Quantitative Gated SPECT (QGS) Gamma Camera System Common Name: System, Emission Computed Tomography Classification Name:

C. Predicate Device:	ADAC CEQUAL®Sopha Sophy NXT
----------------------	---------------------------------

Device Description: D.

{1}------------------------------------------------

E. Indications for Use:
The AutoQUANT , Quantitative Perfusion SPECT (QPS), and Quantitative Gated SPECT (QGS) applications are intended to enable a fully automated review and quantification of Cardiac SPECT data.
F. Technological Comparison:
The AutoQUANT, OPS, QGS, ADAC CEQUAL, and Sopha Sophy NXT Cardiac Software applications have similar indications for use and utilize the same type of data sets for analysis and calculation of data. The ADAC QPS, OGS, CEQUAL, and Sophy NXT Cardiac Software perform the same calculations and analyses on the data sets.

{2}------------------------------------------------

II. Testing

Testing was conducted to demonstrate that each software application functioned as per its specifications. All tests passed with the actual results matching the expected results.

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The eagle is depicted in black and white, and the text is also in black.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

6 1998 MAY

Dennis W. Henkelman Director, Regulatory Affairs and Quality Assurance ADAC Laboratories 540 Alder Drive Milpitas, CA 95035

Re:

K980715 AutoQUANT (Gamma Camera System) Dated: February 23, 1998 Received: February 24, 1998 Regulatory class: II 21 CFR 892.1200/Procode: 90 KPS

Dear Mr. Henkelman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalion assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Thease note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmaldsmamain.html".

Sincerely yours,

Lillian Yin, Ph.D. Director, Division of Reproductive Abdominal, Ear, Nose and Throat and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

INDICATIONS FOR USE STATEMENT

510(k) Number (if known):

Device Name: AutoQUANT Quantitative Perfusion SPECT (QPS) Quantitative Gated SPECT (QGS)

ADAC Laboratories Sponsor Name:

Indications for Use

The AutoQUANT, Quantitative Perfusion SPECT (QPS), and Quantitative Gated SPECT (QGS) applications are intended to enable a fully automated review and quantification of Cardiac SPECT data.

Do Not Write Below This Line - Continue on Another Page if Needed

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use Over-The-Counter Use

David H. Segerson

(Division Sign-Off)

Division of Reproductive, Abdominal, EN and Radiological Dev 510(k) Number

Regulation Number and Section

§ 892.1200 Emission computed tomography system.

(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.